Enzo Biochem Inc. (NYSE: ENZ) reports Q3 earnings loss of $0.15 versus consensus of $0.09 loss. Enzo Biochem Inc. reports revenues of $24.9 million versus consensus of $24.58 million.
Cash, cash equivalents and short-term investments...(read more
Enzo Biochem, Inc. (NYSE: ENZ) today reported results for the fiscal fourth quarter, consistent with our announcement on September 20, 2010, and for the year ended July 31, 2010.
In the fourth quarter of fiscal 2010, compared to a...(read more
I recently got a letter from a reader wondering what I thought about Enzo BioChem (ENZ). ENZ is a life sciences and biotechnology company that provides diagnostic services to the medical...(read more